A Phase 2 clinical trial to evaluate SPY002 (anti-TL1A) in Rheumatoid arthritis patients
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs SPY 002 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Spyre Therapeutics
- 17 Jan 2025 New trial record
- 13 Jan 2025 According to Spyre Therapeutics media release, the trial initiation is expected in mid-2025 with topline results in 2026.